Despite this, CDK4/6 inhibitors have demonstrated minimal effects on survival outcomes in HNSCC or in other solid tumors with Cyclin D-CDK4/6 pathway alterations [59,60]. This evidence concerns the gene CDK4 and head and neck squamous cell carcinoma.